Zenon Biotech

Executive Summary

Zenon Biotech is a preclinical-stage biotechnology company headquartered in Cambridge, Massachusetts, founded in 2018. The company is pioneering first-in-class 'mechano-therapeutics' that target cellular mechano-sensors to treat cancer and fibro-inflammatory diseases such as idiopathic pulmonary fibrosis (IPF) and inflammatory bowel disease (IBD). Its proprietary platform leverages mechanobiology to address disease progression driven by tissue stiffness, a largely untapped mechanism of action. While still in the preclinical phase, Zenon's innovative approach has the potential to differentiate itself in the competitive oncology and fibrosis landscapes. The company's success hinges on advancing its lead candidates into the clinic and demonstrating proof-of-concept in animal models. Given the early stage, the risk is high, but the mechanistic novelty offers significant upside if validated.

Upcoming Catalysts (preview)

• Q4 2026Preclinical data presentation for lead IPF candidate at a major medical conference70% success
• Q1 2027IND filing for lead oncology program50% success
• Q2 2027Series A or B financing round to support clinical development60% success